Carisma Therapeutics Announces Expansion of Its Scientific Advisory Board

Core Insights - Carisma Therapeutics Inc. has appointed Dr. Scott Friedman and Dr. Ira Tabas to its Scientific Advisory Board, enhancing its expertise in liver fibrosis research [1][2] Group 1: Company Overview - Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies using a proprietary macrophage and monocyte cell engineering platform [8] - The company aims to create transformative treatments for cancer and other serious diseases, leveraging the role of engineered macrophages and monocytes in the immune response [8] Group 2: Key Appointments - Dr. Scott Friedman is recognized for his pioneering research in liver fibrosis and has authored over 300 peer-reviewed publications [3][4] - Dr. Ira Tabas has extensively studied pathways involved in metabolic dysfunction-associated steatohepatitis (MASH) fibrosis and has published approximately 300 original research articles [5][6] Group 3: Expertise and Contributions - Dr. Friedman has made significant contributions to understanding liver disease, including isolating the hepatic stellate cell, which is crucial for scar production in the liver [2][3] - Dr. Tabas's research has led to discoveries related to macrophage functions in liver health and disease, contributing to drug development efforts [5][6]